Менопауза и более ранние годы могут вызывать определенные трудности у
женщин с диабетом. Менопауза - это этап жизни после прекращения менструации и
падения уровня эстрогена. Менопауза также может возникнуть в результате операции
по удалению яичников по другим медицинским показаниям. Диабет и менопауза могут
иметь различные последствия для организма, в том числе: высокий уровень сахара в
крови, развитие инфекций, нарушения сна, увеличение веса и сексуальные проблемы.
Обычно некоторые изменения в организме во время менопаузы повышают риск
развития диабета 2 типа: метаболизм замедляется, и организм не так эффективно
сжигает калории, что может привести к увеличению веса. Таким образом, в этой статье
мы обсудим метаболические процессы, происходящие в организме при диабете и
климаксе.
Менопауза и более ранние годы могут вызывать определенные трудности у
женщин с диабетом. Менопауза - это этап жизни после прекращения менструации и
падения уровня эстрогена. Менопауза также может возникнуть в результате операции
по удалению яичников по другим медицинским показаниям. Диабет и менопауза могут
иметь различные последствия для организма, в том числе: высокий уровень сахара в
крови, развитие инфекций, нарушения сна, увеличение веса и сексуальные проблемы.
Обычно некоторые изменения в организме во время менопаузы повышают риск
развития диабета 2 типа: метаболизм замедляется, и организм не так эффективно
сжигает калории, что может привести к увеличению веса. Таким образом, в этой статье
мы обсудим метаболические процессы, происходящие в организме при диабете и
климаксе.
Menopauza undan oldingi yillar diabetga chalingan ayollar uchun ba'zi qiyinchiliklarni
keltirib chiqarishi mumkin. Menopauza - bu hayz ko'rish to'xtatilgandan va estrogen
darajasining pasayishidan keyingi hayot bosqichidir. Menopauza, shuningdek, boshqa tibbiy
sabablarga ko'ra, tuxumdonlar olib tashlangan jarrohlik natijasida ham paydo bo'lishi
mumkin. Qandli diabet va menopauza tanaga turli xil ta'sir ko'rsatishi mumkin, jumladan:
qondagi yuqori shakar miqdori, infektsiyalarning rivojlanishi, uyquning buzilishi, vazn ortishi
va jinsiy muammolar. Odatda, menopauza paytida tanadagi ba'zi o'zgarishlar 2-toifa diabet
xavfini oshiradi: Metabolizm sekinlashadi va organizm kaloriyalarni unchalik samarali
yoqmaydi, bu esa kilogramm ortishiga olib kelishi mumkin. Shunday qilib, ushbu maqolada
biz qandli diabet va menopauza holatlarida organizmda kechadigan metabolik jarayonlar
haqida muhokama qilamiz.
Menopause — and the years before it — may provide some challenges for women who
have diabetes. Menopause is the phase of life after your periods have stopped and your
estrogen levels decline. Menopause can also occur as a result of surgery, when the ovaries are
removed for other medical reasons. Diabetes and menopause may team up for varied effects
on body, including: Changes in blood sugar level, weight gain, infections, sleep problems and
sexual problems. Usually some of the changes that occur in body during menopause put you at
greater risk of type 2 diabetes: Metabolism slows down and organism don't burn calories as
efficiently, which can lead to weight gain. Thus, in this article we will discuss the metabolic
processes that take place in the body in cases of diabetes and menopause.
| № | Author name | position | Name of organisation |
|---|---|---|---|
| 1 | Yusupova S.K. | . | Андижанский Государственный медицинский институт |
| 2 | Salieva S.B. | . | Андижанский Государственный медицинский институт |
| № | Name of reference |
|---|---|
| 1 | 1. Mauvais-Jarvis, F., Manson, J. E., Stevenson, J. C., & Fonseca, V. A. (2017). Menopausal Hormone Therapy and Type 2 Diabetes Prevention: Evidence, Mechanisms, and Clinical Implications. Endocrine Reviews, 38(3), 173–188. doi:10.1210/er.2016-1146 |
| 2 | 2. Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV, Santen RJ 2015 Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 100:3975-4011 |
| 3 | 3. Manson JE, Ames JM, Shapiro M, Gass ML, Shifren JL, Stuenkel CA, Pinkerton JV, Kaunitz AM, Pace DT, Kagan R, Schnatz PF, Kingsberg SA, Liu JH, Joffe H, Richard-Davis G, Goldstein SR, Schiff I, Utian WH 2015 Algorithm and mobile app for menopausal symptom management and hormonal/non-hormonal therapy decision making: a clinical decision-support tool from The North American Menopause Society. Menopause 22:247-253 |
| 4 | 4. Goff DC, Jr., Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, Greenland P, Lackland DT, Levy D, O'Donnell CJ, Robinson JG, Schwartz JS, Shero ST, Smith SC, Jr., Sorlie P, Stone NJ, Wilson PW, Jordan HS, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Tomaselli GF 2014 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129:S49-73 |
| 5 | 5. Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, Anderson G, Howard BV, Thomson CA, LaCroix AZ, WactawskiWende J, Jackson RD, Limacher M, Margolis KL, Wassertheil-Smoller S, Beresford SA, Cauley JA, Eaton CB, Gass M, Hsia J, Johnson KC, Kooperberg C, Kuller LH, Lewis CE, Liu S, Martin LW, Ockene JK, O'Sullivan MJ, Powell LH, Simon MS, Van Horn L, Vitolins MZ, Wallace RB 2013 Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 310:1353-1368 |
| 6 | 6. Manson JE, Kaunitz AM 2016 Menopause Management--Getting Clinical Care Back on Track. N Engl J Med 374:803-806 |
| 7 | 7. Salpeter SR, Walsh JM, Ormiston TM, Greyber E, Buckley NS, Salpeter EE 2006 Meta- analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 8:538-554 |
| 8 | 8. Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, Newby LK, Pina IL, Roger VL, Shaw LJ, Zhao D, Beckie TM, Bushnell C, D'Armiento J, Kris-Etherton PM, Fang J, Ganiats TG, Gomes AS, Gracia CR, Haan CK, Jackson EA, Judelson DR, Kelepouris E, Lavie CJ, Moore A, Nussmeier NA, Ofili E, Oparil S, Ouyang P, Pinn VW, Sherif K, Smith SC, Jr., Sopko G, Chandra-Strobos N, Urbina EM, Vaccarino V, Wenger NK 2011 Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the american heart association. Circulation 123:1243-1262 |
| 9 | 9. Hofman A, Brusselle GG, Darwish Murad S et al (2015) The Rotterdam study: 2016 objectives and design update. Eur J Epidemiol 30:661–708 |
| 10 | 10. Muka, T., Asllanaj, E., Avazverdi, N., Jaspers, L., Stringa, N., Milic, J., ... Franco, O. H. (2017). Age at natural menopause and risk of type 2 diabetes: a prospective cohort study. Diabetologia, 60(10), 1951–1960. doi:10.1007/s00125-017-4346-8 |
| 11 | 11. Ihara K, Fukano C, Ayabe T et al (2017) FUT2 non-secretor status is associated with type 1 diabetes susceptibility in Japanese children. Diabet Med 34:586–589 |
| 12 | 12. Malacara JM, Huerta R, Rivera B, Esparza S, Fajardo ME (1997) Menopause in normal and uncomplicated NIDDM women: physical and emotional symptoms and hormone profile. Maturitas 28:35–45 |
| 13 | 13. Di Donato P, Giulini NA, Bacchi Modena A et al (2005) Risk factors for type 2 diabetes in women attending menopause clinics in Italy: a cross-sectional study. Climacteric 8:287–293 |
| 14 | 14. Luborsky JL, Meyer P, Sowers MF, Gold EB, Santoro N (2003) Premature menopause in a multi-ethnic population study of the menopause transition. Hum Reprod 18:199–206 |
| 15 | 15. Brand JS, van der Schouw YT, Onland-Moret NC et al (2013) Age at menopause, reproductive life span, and type 2 diabetes risk: results from the EPIC-InterAct study. Diabetes Care 36:1012–1019 |
| 16 | 16. Godsland IF (2005) Oestrogens and insulin secretion. Diabetologia 48:2213–2220 28 |
| 17 | 17. Stubbins RE, Najjar K, Holcomb VB, Hong J, Nunez NP (2012) Oestrogen alters adipocyte biology and protects female mice from adipocyte inflammation and insulin resistance. Diabetes Obes Metab 14:58–66 |
| 18 | 18. Kanaya AM, Herrington D, Vittinghoff E et al (2003) Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, doubleblind, placebo-controlled trial. Ann Intern Med 138:1–9 |
| 19 | 19. Margolis KL, Bonds DE, Rodabough RJ et al (2004) Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women’s Health Initiative Hormone Trial. Diabetologia 47:1175–1187 |
| 20 | 20. Bonds DE, Lasser N, Qi L et al (2006) The effect of conjugated equine oestrogen on diabetes incidence: the Women’s Health Initiative randomised trial. Diabetologia 49:459–468 |
| 21 | 21. Ding EL, Song Y, Manson JE, Rifai N, Buring JE, Liu S (2007) Plasma sex steroid hormones and risk of developing type 2 diabetes in women: a prospective study. Diabetologia 50:2076– 2084 |
| 22 | 22. Kalyani RR, Franco M, Dobs AS et al (2009) The association of endogenous sex hormones, adiposity, and insulin resistance with incident diabetes in postmenopausal women. J Clin Endocrinol Metab 94:4127–4135 |
| 23 | 23. Golden SH, Dobs AS, Vaidya D et al (2007) Endogenous sex hormones and glucose tolerance status in postmenopausal women. J Clin Endocrinol Metab 92:1289–1295 |
| 24 | 24. Goodman-Gruen D, Barrett-Connor E (2000) Sex differences in the association of endogenous sex hormone levels and glucose tolerance status in older men and women. Diabetes Care 23:912–918 |
| 25 | 25. Livingstone C, Collison M (2002) Sex steroids and insulin resistance. Clin Sci (Lond) 102:151–166 |
| 26 | 26. Lakshman R, Forouhi N, Luben R et al (2008) Association between age at menarche and risk of diabetes in adults: results from the EPIC-Norfolk cohort study. Diabetologia 51:781– 786 |
| 27 | 27. He C, Zhang C, Hunter DJ et al (2010) Age at menarche and risk of type 2 diabetes: results from 2 large prospective cohort studies. Am J Epidemiol 171:334–344 |
| 28 | 28. Wang N, Kuang L, Han B et al (2016) Follicle-stimulating hormone associates with prediabetes and diabetes in postmenopausal women. Acta Diabetol 53:227–236 |
| 29 | 29. Rocca WA, Shuster LT, Grossardt BR et al (2009) Long-term effects of bilateral oophorectomy on brain aging: unanswered questions from the Mayo Clinic Cohort Study of Oophorectomy and Aging. Womens Health (Lond) 5:39–48 |
| 30 | 30. Taneri PE, Kiefte-de Jong JC, Bramer WM, Daan NM, Franco OH, Muka T (2016) Association of alcohol consumption with the onset of natural menopause: a systematic review and meta-analysis. Hum Reprod Update 22:516–528 |
| 31 | 31. Jackson SP, Bartek J (2009) The DNA-damage response in human biology and disease. Nature 461:1071–1078 |
| 32 | 32. Shimizu I, Yoshida Y, Suda M, Minamino T (2014) DNA damage response and metabolic disease. Cell Metab 20:967–977 |
| 33 | 33. Muka T, Nano J, Voortman T et al (2016) The role of global and regional DNA methylation and histone modifications in glycemic traits and type 2 diabetes: a systematic review. Nutr Metab Cardiovasc Dis 26:553–566 |
| 34 | 34. den Tonkelaar I (1997) Validity and reproducibility of self-reported age at menopause in women participating in the DOM-project. Maturitas 27:117–123 |
| 35 | 35. Braem MG, Voorhuis M, van der Schouw YT et al (2013) Interactions between genetic variants in AMH and AMHR2 may modify age at natural menopause. PLoS One 8:e59819 |
| 36 | 36. Hu FB, Grodstein F, Hennekens CH et al (1999) Age at natural menopause and risk of cardiovascular disease. Arch Intern Med 159:1061–1066 |
| 37 | 37. Brand JS, Onland-Moret NC, Eijkemans MJ et al (2015) Diabetes and onset of natural menopause: results from the European Prospective Investigation into Cancer and Nutrition. Hum Reprod 30:1491–1498 |
| 38 | 38. Willis D, Mason H, Gilling-Smith C, Franks S. Modulation by insulin of follicle-stimulating hormone and luteinizing hormone actions in human granulosa cells of normal and polycystic ovaries. J Clin Endocrinol Metab 1996; 81: 302–09 |
| 39 | 39. Fulghesu AM, Villa P, Pavone V, et al. The impact of insulin secretion on the ovarian response to exogenous gonadotropins in polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82: 644–48 |
| 40 | 40. Willis DS, Watson H, Mason HD, Galea R, Brincat M, Franks S. Premature response to luteinizing hormone of granulosa cells from anovulatory women with polycystic ovary syndrome: relevance to mechanism of anovulation. J Clin Endocrinol Metab 1998; 83: 3984– 91 |
| 41 | 41. Franks S, Mason H, White D, Willis D. Etiology of anovulation in polycystic ovary syndrome. Steroids 1998; 63: 306–07 |